We also possess a proprietary-asset-enabled antibody-generating technology. CMS made separate payment for OMIDRIA effective retroactively as of October 1, 2020. This is referred to as the "complete response rate." All of these are common causes of death in this patient population. The trial is designed to allow intra-trial adjustment in sample size. MASP-3 Program - OMS906 - Alternative Pathway DisordersOverview. Preclinical Programs and PlatformsGPCR PlatformOverview. OMIDRIA is encompassed by our PharmacoSurgery patent portfolio. Drug Supply Chain Security Act. Timothy M. Duffy has served as our vice president, business development since March 2010. These are not the only risks we face. Our BLA for narsoplimab for the treatment of HSCT-TMA is under priority review by FDA. Our operating results are unpredictable and may fluctuate. In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. These fluctuations may be even more pronounced in the trading market for our stock.